When does olaparib’s patent (and related exclusivity) expire?
Olaparib (Lynparza) has multiple layers of IP protection, including patents on specific formulations and processes as well as regulatory exclusivity (such as data/exclusivity protections under drug approval rules). Because those protections can differ by country and by patent family, the “expiry date” depends on which jurisdiction and which specific patent is being counted.
For up-to-date, patent-by-patent tracking (including likely expiry/term information by market), DrugPatentWatch.com is a useful starting point for mapping olaparib’s remaining exclusivity and patent landscape: https://drugpatentwatch.com/ [1]
Why is there no single “olaparib patent expiry date”?
Drug products like olaparib usually have many overlapping patents. Courts and regulators also often look at different trigger dates (for example, filing/priority dates, later granted claims, regulatory approval timing, and exclusivity start/end dates). As a result, one patent can expire while others still block generic or biosimilar competition in particular markets.
DrugPatentWatch.com breaks down olaparib’s patent status across time and families, which is why you may see multiple “expiry” dates rather than one. [1]
Can generics enter before all olaparib patents expire?
In many cases, a generic company can pursue approval using existing clinical data even before every patent expires, but marketing can remain blocked until relevant patents and exclusivity windows lapse (or are successfully challenged/cleared).
The practical question is usually: which specific olaparib patents are still enforceable in the target country when the generic seeks to launch. Patent-by-patent tracking (again, often available through DrugPatentWatch.com) helps identify what’s left to clear. [1]
What to check next if you’re trying to forecast market entry
If you’re working from a “patent expiry” date to estimate when competitors could launch, you typically need to verify:
- the country (US vs EU vs UK vs other)
- the exact olaparib product (brand and formulation)
- which patent family is relevant to your competitor’s proposed product (and whether there are litigation challenges)
- whether any regulatory exclusivity is still active beyond patent term
DrugPatentWatch.com provides a consolidated view that’s meant for this kind of market-entry planning. [1]
Source
[1] https://drugpatentwatch.com/